REVIEWS   

Acta Vulnologica 2009 June;7(2):91-100

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: Italian

Design and production of a homologous cell-free skin substitute: results obtained by in vitro and preclinical studies

Bondioli E. ¹, Benini A. ¹, Carboni A. ¹, D’Acunto C. ¹, Frassetto A. ¹, Orioli R. ¹, Orlandi C. ¹, Fini M. ², Giavaresi G. ², Torricelli P. ², Rotini R. ³, Cerasoli S. ⁴, Cenacchi G. ⁵, Giardino R. ², Melandri D. ¹

¹ Unità Operativa Centro Grandi Ustionati e Banca Regionale della Cute Emilia Romagna Ospedale M. Bufalini Azienda USL Cesena, Cesena, Italia 2 Laboratorio di Studi Preclinici Chirurgici Istituto Ortopedico Rizzoli (IOR), Bologna, Italia 3 Sezione “B” di Chirurgia Ortopedica Traumatologica Istituto Ortopedico Rizzoli (IOR), Bologna, Italia 4 Unità Operativa di Anatomia Patologica Ospedale M. Bufalini Azienda USL Cesena,Cesena, Italia 5 Laboratorio di Patologia e Diagnostica Subcellulare Dipartimento Clinico di Scienze Radiologiche e Istocitopatologiche Università degli Studi di Bologna, Bologna, Italia

Design and production of a homologous cell-free skin substitute: results obtained by in vitro and preclinical studies In recent years the market, with the help of modern biotechnology has marketed several skin substitutes summary in nature syntetic and/or biosyntetic used increasingly for the treatment of wounds, such as chronic skin ulcers varied etiology, a disease significantly affecting quality of life of the patients and carrying a high load of economic resources in health. At the Regional Skin Bank of Emilia Romagna and Burn Center - AUSL Cesena, in close synergy with other laboratories for research, a study focused on the design and production of a skin substitute cell-free only from biological counterpart donor dermis multiorgan and/or multitissue. The first part of the study has been oriented strictly to the biological scaffold to assess the presence of all necessary requirements needed for the future clinical use. Therefore studies were performed in vitro and ex vivo cell cultures to demonstrate the absence of cellular components responsible for a possible rejection of the recipient, the architectural integrity of the structure and collagen fiber content, the mechanical strength and malleability of the finished product. These results were then compared with the existing data in the literature regarding other commercial products of the same origin and also of animal origin. The data obtained in the first part of the trial were encouraging; therefore, following Ministerial approval, was performed a preclinical phase of study on an animal model to demonstrate the biocompatibility of the dermal scaffold in terms of absence of rejection and lack of post surgical inflammatory reactions. Studies to date have been very promising for a future clinical use of this dermal scaffold for the treatment of chronic skin ulcers and other areas such as the orthopedic for the repair of the rotator cuff of the shoulder.